Bio-Rad feels unloved by the investment community
This article was originally published in Clinica
Executive Summary
We are somewhat undervalued in the financial market," Bio-Rad's vice-president, Norman Schwartz, told a recent UBS Warburg Global Life Sciences conference in New York. Explaining how the $700 million turnover company derives its income for life sciences laboratory analysis and clinical diagnostics, he characterised Bio-Rad as a company "providing tools for discovery and for diagnostic testing".